BRAF and neoplasm: Precise assessment of BRAF mutation status is essential not only for definitive tumor diagnosis and effective anti-BRAF targeted therapy (e.g., vemurafenib and dabrafenib) but also for providing crucial prognostic information regarding the nodule’s biological behavior and potential aggressiveness (9, 10).